The frequency and inter-relationship of PD-L1 expression and tumour mutational burden across multiple types of advanced solid tumours in China
Abstract Background PD-L1 expression and tumour mutational burden (TMB) are both associated with the responses of multiple tumours to immune checkpoint inhibitor (ICI) therapy. However, their prevalence and correlations may differ in different types of advanced solid tumours. Methods PD-L1 expressio...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-08-01
|
Series: | Experimental Hematology & Oncology |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s40164-020-00173-3 |
id |
doaj-301929f987174ea1a6ce877b5bc03101 |
---|---|
record_format |
Article |
spelling |
doaj-301929f987174ea1a6ce877b5bc031012020-11-25T03:07:54ZengBMCExperimental Hematology & Oncology2162-36192020-08-019111310.1186/s40164-020-00173-3The frequency and inter-relationship of PD-L1 expression and tumour mutational burden across multiple types of advanced solid tumours in ChinaYanhui Chen0Yating Wang1Hongli Luo2Xue Meng3Wei Zhu4Di Wang5Hui Zeng6Henghui Zhang7Institute of Infectious Diseases, Beijing Ditan Hospital, Key Laboratory of Emerging Infectious Diseases, Capital Medical UniversityGenecast Biotechnology Co., Ltd.Genecast Biotechnology Co., Ltd.Genecast Biotechnology Co., Ltd.Genecast Biotechnology Co., Ltd.Genecast Biotechnology Co., Ltd.Institute of Infectious Diseases, Beijing Ditan Hospital, Key Laboratory of Emerging Infectious Diseases, Capital Medical UniversityInstitute of Infectious Diseases, Beijing Ditan Hospital, Key Laboratory of Emerging Infectious Diseases, Capital Medical UniversityAbstract Background PD-L1 expression and tumour mutational burden (TMB) are both associated with the responses of multiple tumours to immune checkpoint inhibitor (ICI) therapy. However, their prevalence and correlations may differ in different types of advanced solid tumours. Methods PD-L1 expression, TMB, and PD-1+ Tils (tumour-infiltrating lymphocytes) infiltration and their relationships were assessed in 6668 advanced solid tumour specimens across 25 tumour types. CD8+ T cell infiltration was analysed in 347 NSCLC samples. The associations of these biomarkers with the therapeutic effect of PD-1 inhibitor were analysed in a cohort of NSCLC samples. Results PD-L1 expression levels and TMB in different tumour types varied widely and their relationship was not significantly correlated in most cancer types, with only a small association across all specimens (Spearman R = 0.059). PD-1+ Tils infiltration was positively correlated with PD-L1 expression across all samples (Spearman R = 0.3056). However, there is no such correlation between PD-1+ Tils infiltration and TMB. In NSCLC samples, CD8+ T cell infiltration was correlated with PD-1+ Tils infiltration and PD-L1 expression but not with TMB (Spearman R = 0.4117, 0.2045, and 0.0007, respectively). Patients in the CR/PR group (anti-PD-1 therapy) had higher levels of PD-L1 expression, TMB, PD-1+ Tils, and CD8+ T cell infiltration, and many patients in this group exhibited concomitantly elevated levels of multiple biomarkers. Conclusions Our results showed the PD-L1 expression status and TMB in various types of advanced solid tumours in Chinese patients and their relationships with PD-1+ Tils and CD8+ T cell infiltration, which may inform ICI treatment.http://link.springer.com/article/10.1186/s40164-020-00173-3PD-L1TMBPD-1Solid tumourImmunotherapy |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Yanhui Chen Yating Wang Hongli Luo Xue Meng Wei Zhu Di Wang Hui Zeng Henghui Zhang |
spellingShingle |
Yanhui Chen Yating Wang Hongli Luo Xue Meng Wei Zhu Di Wang Hui Zeng Henghui Zhang The frequency and inter-relationship of PD-L1 expression and tumour mutational burden across multiple types of advanced solid tumours in China Experimental Hematology & Oncology PD-L1 TMB PD-1 Solid tumour Immunotherapy |
author_facet |
Yanhui Chen Yating Wang Hongli Luo Xue Meng Wei Zhu Di Wang Hui Zeng Henghui Zhang |
author_sort |
Yanhui Chen |
title |
The frequency and inter-relationship of PD-L1 expression and tumour mutational burden across multiple types of advanced solid tumours in China |
title_short |
The frequency and inter-relationship of PD-L1 expression and tumour mutational burden across multiple types of advanced solid tumours in China |
title_full |
The frequency and inter-relationship of PD-L1 expression and tumour mutational burden across multiple types of advanced solid tumours in China |
title_fullStr |
The frequency and inter-relationship of PD-L1 expression and tumour mutational burden across multiple types of advanced solid tumours in China |
title_full_unstemmed |
The frequency and inter-relationship of PD-L1 expression and tumour mutational burden across multiple types of advanced solid tumours in China |
title_sort |
frequency and inter-relationship of pd-l1 expression and tumour mutational burden across multiple types of advanced solid tumours in china |
publisher |
BMC |
series |
Experimental Hematology & Oncology |
issn |
2162-3619 |
publishDate |
2020-08-01 |
description |
Abstract Background PD-L1 expression and tumour mutational burden (TMB) are both associated with the responses of multiple tumours to immune checkpoint inhibitor (ICI) therapy. However, their prevalence and correlations may differ in different types of advanced solid tumours. Methods PD-L1 expression, TMB, and PD-1+ Tils (tumour-infiltrating lymphocytes) infiltration and their relationships were assessed in 6668 advanced solid tumour specimens across 25 tumour types. CD8+ T cell infiltration was analysed in 347 NSCLC samples. The associations of these biomarkers with the therapeutic effect of PD-1 inhibitor were analysed in a cohort of NSCLC samples. Results PD-L1 expression levels and TMB in different tumour types varied widely and their relationship was not significantly correlated in most cancer types, with only a small association across all specimens (Spearman R = 0.059). PD-1+ Tils infiltration was positively correlated with PD-L1 expression across all samples (Spearman R = 0.3056). However, there is no such correlation between PD-1+ Tils infiltration and TMB. In NSCLC samples, CD8+ T cell infiltration was correlated with PD-1+ Tils infiltration and PD-L1 expression but not with TMB (Spearman R = 0.4117, 0.2045, and 0.0007, respectively). Patients in the CR/PR group (anti-PD-1 therapy) had higher levels of PD-L1 expression, TMB, PD-1+ Tils, and CD8+ T cell infiltration, and many patients in this group exhibited concomitantly elevated levels of multiple biomarkers. Conclusions Our results showed the PD-L1 expression status and TMB in various types of advanced solid tumours in Chinese patients and their relationships with PD-1+ Tils and CD8+ T cell infiltration, which may inform ICI treatment. |
topic |
PD-L1 TMB PD-1 Solid tumour Immunotherapy |
url |
http://link.springer.com/article/10.1186/s40164-020-00173-3 |
work_keys_str_mv |
AT yanhuichen thefrequencyandinterrelationshipofpdl1expressionandtumourmutationalburdenacrossmultipletypesofadvancedsolidtumoursinchina AT yatingwang thefrequencyandinterrelationshipofpdl1expressionandtumourmutationalburdenacrossmultipletypesofadvancedsolidtumoursinchina AT hongliluo thefrequencyandinterrelationshipofpdl1expressionandtumourmutationalburdenacrossmultipletypesofadvancedsolidtumoursinchina AT xuemeng thefrequencyandinterrelationshipofpdl1expressionandtumourmutationalburdenacrossmultipletypesofadvancedsolidtumoursinchina AT weizhu thefrequencyandinterrelationshipofpdl1expressionandtumourmutationalburdenacrossmultipletypesofadvancedsolidtumoursinchina AT diwang thefrequencyandinterrelationshipofpdl1expressionandtumourmutationalburdenacrossmultipletypesofadvancedsolidtumoursinchina AT huizeng thefrequencyandinterrelationshipofpdl1expressionandtumourmutationalburdenacrossmultipletypesofadvancedsolidtumoursinchina AT henghuizhang thefrequencyandinterrelationshipofpdl1expressionandtumourmutationalburdenacrossmultipletypesofadvancedsolidtumoursinchina AT yanhuichen frequencyandinterrelationshipofpdl1expressionandtumourmutationalburdenacrossmultipletypesofadvancedsolidtumoursinchina AT yatingwang frequencyandinterrelationshipofpdl1expressionandtumourmutationalburdenacrossmultipletypesofadvancedsolidtumoursinchina AT hongliluo frequencyandinterrelationshipofpdl1expressionandtumourmutationalburdenacrossmultipletypesofadvancedsolidtumoursinchina AT xuemeng frequencyandinterrelationshipofpdl1expressionandtumourmutationalburdenacrossmultipletypesofadvancedsolidtumoursinchina AT weizhu frequencyandinterrelationshipofpdl1expressionandtumourmutationalburdenacrossmultipletypesofadvancedsolidtumoursinchina AT diwang frequencyandinterrelationshipofpdl1expressionandtumourmutationalburdenacrossmultipletypesofadvancedsolidtumoursinchina AT huizeng frequencyandinterrelationshipofpdl1expressionandtumourmutationalburdenacrossmultipletypesofadvancedsolidtumoursinchina AT henghuizhang frequencyandinterrelationshipofpdl1expressionandtumourmutationalburdenacrossmultipletypesofadvancedsolidtumoursinchina |
_version_ |
1724668558276820992 |